Perimenopause Supplements Compared: Ingredients, Claims, and Evidence Gaps

We may earn money or products from the companies mentioned in this post.

Perimenopause supplement marketing can make very different products sound interchangeable. Before spending money, it helps to separate what each formula contains, what its manufacturer claims, and what the research can actually establish.

This comparison covers Amberen Perimenopause Relief, Equelle, Bonafide Relizen, and Bonafide Serenol. It is a research-based review, not a report of personal product testing.

Quick Answer: Is There a Best Perimenopause Supplement?

There is no universal winner. These products have different formulations and intended uses, and evidence from a study of one ingredient or population does not automatically establish effectiveness for a current product used during perimenopause.

The North American Menopause Society’s 2023 nonhormone therapy position statement did not recommend supplements or herbal remedies for treating vasomotor symptoms, meaning hot flashes and night sweats. It also did not recommend soy foods, soy extracts, or the soy metabolite equol for that purpose. These recommendations concern symptom treatment, not whether every supplement is ineffective for every possible use.

The practical starting point is to identify the symptom that needs attention and discuss evidence-supported options with a healthcare professional before committing to a supplement subscription.

Quick Side-by-Side Comparison

The intended uses below are manufacturer claims, not independent endorsements. Product information and prices were checked on October 28, 2026; formulas, offers, and availability can change.

Product	Main formulation	Manufacturer-stated focus	Important consideration	Main evidence limitation
Amberen Perimenopause Relief	Proprietary succinate-based complex with B vitamins	Multiple perimenopause symptoms	A proprietary complex limits ingredient-by-ingredient assessment	A relevant trial studied Amberen combined with Smart B; applicability depends on matching the studied formulation
Equelle	Soy-derived S-equol; formulation also contains calcium	Menopause symptoms, including hot flashes	Contains soy; medication timing may need review	Much of the cited research concerns postmenopausal women or equol formulations rather than this exact product during perimenopause
Bonafide Relizen	Purified Swedish flower pollen extract blend	Hot flashes and night sweats	Review the specific label and allergy history with a clinician	Small studies of related pollen preparations do not establish broad perimenopause benefits
Bonafide Serenol	Swedish flower pollen blend, royal jelly, and chromium picolinate	Emotional symptoms associated with PMS and menopause	Manufacturer says to avoid it with bee or bee-product allergies	Evidence for one ingredient or for PMS should not be generalized to all perimenopause symptoms

What Each Product Offers—and What Remains Uncertain

Amberen Perimenopause Relief

Amberen’s official product page describes a hormone-free, soy-free formula combining a proprietary succinate-based complex with B vitamins. Its marketing covers several symptoms, including hot flashes, sleep difficulties, low energy, and irritability.

An important distinction is that a 2024 randomized, double-blind, placebo-controlled trial evaluated Amberen combined with Smart B, rather than establishing that every Amberen formulation is equivalent. The study enrolled 106 participants, with 105 completing it, and reported improvements on several symptom measures in women with mild-to-moderate perimenopausal symptoms.

The study is relevant because it included perimenopausal women. However, its findings should be interpreted in the context of its duration, participant selection, and formulation. One author’s affiliation was Alliance Pharma/Alliance Pharmaceuticals, which is relevant commercial context rather than a reason to dismiss the results automatically.

Pros: A perimenopause-specific focus and a placebo-controlled study in a relevant population.

Limitations: Proprietary ingredient disclosure and uncertainty about how well the results generalize to other formulations, more severe symptoms, or people with different medical histories.

Equelle S-equol

Equelle contains S-equol, a metabolite of a soy isoflavone with structural similarity to estrogen. Its manufacturer describes a daily serving of two tablets providing 10 mg. This does not mean it is interchangeable with prescription estrogen.

A pilot trial involving 102 postmenopausal women compared 10, 20, and 40 mg of S-equol daily with soy isoflavones. Reductions in hot flash frequency at week eight were similar across groups. Some cumulative and subgroup analyses favored higher doses. Because the comparator was soy isoflavones, the trial does not establish superiority over placebo, and the higher-dose findings are not instructions to increase Equelle’s labeled dose.

A 2019 systematic review included six studies with 779 participants; five studies with 728 participants contributed to the pooled meta-analysis. The pooled finding favored equol, but two included studies did not find statistically significant benefits. The research was not exclusively a test of current Equelle in perimenopausal women.

Pros: A clearly identified active ingredient and published randomized research on S-equol.

Limitations: Differences in populations, formulations, and comparators limit what those studies establish for an individual reader.

Equelle’s manufacturer advises against use with soy allergy or sensitivity. Because the formula contains calcium, it also advises separating it from iron and thyroid medication. Ask a pharmacist to confirm timing for your particular medicines rather than changing a prescription schedule yourself.

Bonafide Relizen

Relizen is marketed for hot flashes and night sweats. Its formulation uses a proprietary purified Swedish flower pollen blend identified as PI-82 and GC-FEM. Bonafide cites research on pollen preparations, including a 2005 trial of Femal.

That randomized, placebo-controlled trial enrolled 64 menopausal women, of whom 54 completed the study. After three months, 65% of the active-treatment group reported a reduction in hot flashes, compared with 38% of the placebo group. The 38% figure is a response rate—not the number of participants in the placebo group.

Bonafide lists this study among Relizen’s supporting references. However, the publication names Femal as the tested preparation. It should be presented as related pollen-extract research, without assuming that it independently verifies every feature of the current Relizen formulation or establishes benefit for all perimenopause symptoms.

Pros: A clearly defined intended use and supporting placebo-controlled research on a related preparation.

Limitations: A small study, an older tested preparation, and limited grounds for extending hot-flash findings to unrelated symptoms.

If you have allergies, have a clinician or pharmacist assess the actual label. A purified pollen preparation should not be judged solely from its name.

Bonafide Serenol

Serenol combines a Swedish flower pollen blend with royal jelly and chromium picolinate. Bonafide markets it for emotional symptoms associated with PMS and menopause, including irritability and uneasiness, with additional claims involving cravings, bloating, and sleep.

It is not primarily a facial-swelling product, and it should not be treated as interchangeable with a supplement marketed specifically for hot flashes.

The manufacturer discusses ingredient research and customer-reported outcomes. Those forms of evidence need to be distinguished from a large, independent, placebo-controlled trial of the current finished product specifically in perimenopausal women. Results from PMS studies or customer surveys do not establish benefit for every menopausal mood symptom.

Pros: Identifiable key ingredients and an intended use distinct from hot-flash-focused products.

Limitations: Mixed PMS and menopause claims and uncertainty about their applicability to individual perimenopausal symptoms.

Label warning: Bonafide says to avoid Serenol if you are allergic to bees or bee products because it contains royal jelly. Persistent or disruptive mood symptoms deserve medical assessment rather than repeated supplement purchases.

Price Comparison: One-Time Purchases vs. Subscriptions

Compare the total commitment as well as the advertised monthly amount. A lower monthly equivalent can require a substantially larger upfront payment.

Product	One-time purchase	Monthly subscription	Longer prepaid plans
Amberen Perimenopause Relief	No direct purchase price displayed on the official page reviewed	Check the linked retailer	Retailer pricing varies
Equelle	$42	$39.90 per month	$111 paid quarterly; advertised as $37 per month
Relizen	$58, plus $5 shipping	$42 per month	$114 quarterly ($38/month) or $198 every six months ($33/month)
Serenol	$63, plus $5 shipping	$48 per month	$129 quarterly ($43/month) or $222 every six months ($37/month)

Sources: Amberen, Equelle, Relizen, and Serenol. Prices are in US dollars, before any applicable tax. Confirm supply duration, shipping, renewal terms, and checkout totals before purchasing.

A three-month commitment on the listed quarterly plans is $111 for Equelle, $114 for Relizen, or $129 for Serenol. These are budgeting comparisons, not recommendations to use a product for three months.

What the Research Can—and Cannot—Tell You

Positive findings from an individual trial deserve attention, but they are not the same as a consistent body of evidence or a clinical recommendation. Important questions include:

• Who participated? Postmenopausal findings may not transfer directly to women whose cycles are still changing.
• What was tested? An ingredient, a related preparation, a combined regimen, and today’s finished product are different research questions.
• What was the comparison? Improvement compared with another supplement does not establish benefit over placebo.
• How was improvement measured? A response rate, an average symptom reduction, and a customer satisfaction score are not interchangeable.
• How long did the study last? Short-term findings do not settle long-term effectiveness or safety.
• Who supported the work? Commercial involvement should be disclosed and considered alongside study design and independent replication.

The Menopause Society’s patient guidance on hot flashes also describes limited or inconsistent evidence for many supplement approaches. Neither a positive study nor the phrase “clinically studied” makes a product a proven substitute for established treatment.

For broader context, read Navigating Perimenopause: A Guide for Women Balancing Careers and Family.

Questions to Ask Before Buying

Use the comparison to prepare questions rather than to diagnose yourself or select treatment solely from a product description.

1. What symptom needs evaluation? Discuss symptoms that affect sleep, work, relationships, or daily functioning instead of assuming a supplement is the appropriate first step.
2. Does the complete label fit your medical history? Bring the product label, medication list, other supplements, and allergy history to a clinician or pharmacist.
3. Does the evidence match the claim? Look for the same preparation, dose, population, and outcome—not just a study involving a familiar ingredient.
4. What is the full cost? Check upfront payment, shipping, renewal frequency, cancellation terms, and the supply included.
5. How will the decision be reviewed? If a clinician agrees a trial is appropriate, discuss what to track, when to reassess, and what should prompt stopping or seeking care. Do not treat a study’s duration as a universal instruction to keep taking a product.

Symptoms That Should Not Be Managed as a Supplement Experiment

ACOG advises discussing abnormal bleeding with an ob-gyn, including bleeding after sex, bleeding between periods, unusually heavy or prolonged bleeding, and any bleeding after menopause.

Possible emergencies need immediate help. Call 911 in the United States for possible heart attack or stroke symptoms, such as concerning chest discomfort or sudden face drooping, arm weakness, or speech difficulty. Do not attribute these symptoms to perimenopause or wait to see whether a supplement helps. See the American Heart Association’s warning signs.

Frequently Asked Questions

Which supplement works best for perimenopause?

The evidence reviewed does not establish one of these products as a universal best choice. A useful comparison considers the intended symptom, exact formulation, study population, medical history, and cost. Manufacturer positioning should not be mistaken for proof of effectiveness.

Can these supplements be taken together?

Do not assume combining them is appropriate. Relizen and Serenol contain related pollen blends; other ingredients and medicines also need review. Ask a pharmacist or healthcare professional to assess the complete labels before combining products. This comparison does not evaluate combination regimens.

Are hormone-free supplements safer than hormone therapy?

“Hormone-free” does not establish superior safety or effectiveness. The 2023 position statement identifies hormone therapy as the most effective treatment for vasomotor symptoms and describes evidence-supported nonhormone options. Which approach is suitable depends on individual risks, symptoms, and preferences and should be discussed with a clinician.

How long should a supplement be tried?

There is no universal trial period for this category. Follow the current label and a healthcare professional’s advice. Do not exceed labeled doses or continue through adverse effects simply because a study lasted several months. Reassess both benefit and expense rather than allowing a subscription to renew indefinitely.

Does a higher price mean better evidence?

No price in this comparison establishes effectiveness. Compare what the research actually tested and what the label discloses. A more expensive subscription does not resolve uncertainty about whether the product is suitable for you.

Conclusion

These four supplements differ in both formulation and purpose. Amberen’s relevant research involves a combined perimenopause regimen; Equelle’s S-equol research includes important population and comparator limitations; Relizen cites studies of related pollen preparations; and Serenol’s emotional-symptom positioning should not be confused with hot-flash treatment.

The most useful next step is a discussion grounded in your symptoms, health history, and available treatment evidence. If a supplement is considered, review the current label, the applicable research, the full financial commitment, and a plan for reassessment before purchasing.

This article provides general educational information and does not replace individualized medical advice. Product details and prices can change.